



A

REV patients plus HD





**B**

REV patients plus HD








**C**

NKs





Activating receptors

**E**

Inhibitory receptors

**G****H****J****I**

Treg markers



Supplementary Figure S2. Correlation between age and pretreatment NKs and Tregs immune subsets cells in mRCC-REV patients and HDs. Scatter plots from Kendall's rank correlation between age and both pretreatment blood lymphocyte immune cell population (A) NKs and (B) Tregs over the entire cohort (REV+HD) or mRCC-REV patients and HDs. Box and Whisker plot of HD (n=33) and REV (n=33) comparison in (C) age-matched subset from original cohort ranged from 49 and 65 years-old (D) activating NK cell receptors inhibitory NK (E) cell receptors (F) CD107a degranulation (G) PD1⁺CD4 and PD1⁺CD8 T cells (H) Tregs (I) Treg markers and (J). Tregs dependent T cell effector proliferation. Mann-Whitney test, (*p<0.05; **p<0.01; ***p<0.001).